Prognostic value of the tumor-to-liver density ratio in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. A post-hoc study of the STIC-AVASTIN trial.

Date publication

juin 2024

Journal

Cancer imaging : the official publication of the International Cancer Imaging Society

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BORG Christophe , Pr BOUCHE Olivier

Tous les auteurs :
Mazard T, Mollevi C, Loyer EM, Léger J, Chautard R, Bouché O, Borg C, Armand-Dujardin P, Bleuzen A, Assenat E, Lecomte T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38886836

Résumé

The Response Evaluation Criteria in Solid Tumors (RECIST) are often inadequate for the early assessment of the response to cancer therapy, particularly bevacizumab-based chemotherapy. In a first cohort of patients with colorectal cancer liver metastases (CRLM), we showed that variations of the tumor-to-liver density (TTLD) ratio and modified size-based criteria determined using computed tomography (CT) data at the first restaging were better prognostic criteria than the RECIST. The aims of this study were to confirm the relevance of these radiological biomarkers as early predictors of the long-term clinical outcome and to assess their correlation with contrast-enhanced ultrasound (CEUS) parameters in a new patient cohort.

Mots clés

Humans, Bevacizumab, therapeutic use, Colorectal Neoplasms, drug therapy, Liver Neoplasms, secondary, Male, Female, Middle Aged, Aged, Retrospective Studies, Prognosis, Tomography, X-Ray Computed, methods, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Adult, Ultrasonography, methods, Liver, diagnostic imaging

Référence

Cancer Imaging. 2024 06 17;24(1):77